Renal denervation superior to drug therapy in hypertension

The Lancet

Volumn 385, Issue 9981, 2015, Pages 1922-1924

  Hering, Dagmara ^a,b  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IRBESARTAN; NORADRENALIN; PRAZOSIN; RAMIPRIL; RILMENIDINE; SPIRONOLACTONE;

ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR RISK; HUMAN; HYPERTENSION; KIDNEY DENERVATION; KIDNEY DISEASE; MUSCLE SYMPATHETIC NERVE ACTIVITY; NOTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESISTANT HYPERTENSION; SYMPATHETIC NERVE; SYSTOLIC BLOOD PRESSURE; CATHETER ABLATION; DENERVATION; FEMALE; MALE; PROCEDURES;

ANTIHYPERTENSIVE AGENTS; CATHETER ABLATION; DENERVATION; FEMALE; HUMANS; HYPERTENSION; MALE;

EID: 84929606192     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)62050-X     Document Type: Note

References (11)

1. G Mancia, R Fagard, K Narkiewicz et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) J Hypertens 31 2013 1281 1357
2. D Hering, EA Lambert, P Marusic et al. Substantial reduction in single sympathetic nerve firing after renal denervation in patients with resistant hypertension Hypertension 61 2013 457 464
3. D Hering, P Marusic, AS Walton et al. Sustained sympathetic and blood pressure reduction 1 year after renal denervation in patients with resistant hypertension Hypertension 64 2014 118 124
4. GF DiBona, M Esler Translational medicine: the antihypertensive effect of renal denervation Am J Physiol Regul Integr Comp Physiol 298 2010 R245 R253
5. H Krum, M Schlaich, R Whitbourn et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study Lancet 373 2009 1275 1281
6. H Krum, MP Schlaich, PA Sobotka et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study Lancet 383 2014 622 629
7. MD Esler, M Bohm, H Sievert et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial Eur Heart J 35 2014 1752 1759
8. DL Bhatt, DE Kandzari, WW O'Neill et al. A controlled trial of renal denervation for resistant hypertension N Engl J Med 370 2014 1393 1401
9. D Kandzari Lecture on behalf of the Symplicity HTN-3 Investigators. Symplicity HTN-3 trial: analysis of potentially confounding factors http://www.pcronline.com/Lectures/2014/Symplicity-HTN-3-insights-from-the-subgroup-analysis 2014 (accessed May 22, 2014).
10. M Azizi, M Sapoval, P Gosse the Renal Denervation for Hypertension (DENERHTN) investigators Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial Lancet 2015 published online Jan 26. http://dx.doi.org/10.1016/S0140-6736(14)61942-5
11. M Esler Illusions of truths in the Symplicity HTN-3 trial: generic design strengths but neuroscience failings J Am Soc Hypertens 8 2014 593 598